Strong Q4 revenue growth of 92% YoY, significant gross margin improvement from 46% to 69%, successful FDA clearance for SImmetry+ product, record physician adoption metrics, multiple pipeline catalysts expected in 2026, improved cash position through $4.3M financing, and management confidence in sustained growth momentum. Net losses are narrowing despite increased investments in commercial expansion.
Also mentions TNON
Articles that tag TNON but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
